Cerebral Small Vessel Disease: A Field Primer

Purpose and learning objective

The aim is not merely to recognize the abbreviations CAA, WMH, CMB, or STRIVE. The aim is to be able to reason from anatomy to vessel-wall pathology, from vessel-wall pathology to tissue injury, from tissue injury to imaging, and from imaging to a diagnosis without confusing any one layer for another.

The central discipline of this field is inference across scale:

Causal chain: Risk and susceptibility → small-vessel wall and neurovascular-unit change → physiological dysfunction → microscopic tissue injury → visible MRI or CT markers → clinical syndromes and disability. The arrows are not one-to-one: imaging has incomplete etiologic specificity and imperfect sensitivity to microscopic injury.

A visible lesion is therefore an informative footprint, not a transparent photograph of the causal vessel pathology.

1. What counts as cerebral small vessel disease?

"Cerebral small vessel disease" (cSVD) is an umbrella term for disorders affecting small arteries, arterioles, capillaries, and venules of the brain. Many of these vessels are below the resolution of routine clinical imaging. Their presence is inferred from downstream lesions, functional measurements, or tissue examination.

The two most common age-related vessel-wall pathologies are:

Non-amyloid arteriolosclerosis: thickening, stiffening, and remodeling of small penetrating vessels, especially in deep brain and white matter territories. It is associated with age, hypertension, diabetes, and other metabolic or vascular exposures, but these associations are neither exclusive nor sufficient.
Cerebral amyloid angiopathy: deposition of amyloid-beta, particularly Aβ40, in leptomeningeal and cortical vessel walls. Sporadic CAA rises sharply with age and commonly coexists with Alzheimer disease, but it is anatomically and biologically distinct from parenchymal amyloid plaques.

Other cSVDs include monogenic arteriopathies (for example NOTCH3-related CADASIL, HTRA1-related disease, and COL4A1/2 disorders), inflammatory small-vessel disease, immune-mediated CAA-related inflammation, radiation-related vasculopathy, venous collagenosis, and less common protein-deposition angiopathies. These are not peripheral curiosities: they reveal mechanisms and remind us that similar imaging phenotypes can arise from different causes.

A vocabulary trap

"Arteriosclerosis" means hardening/remodeling of arteries broadly. "Atherosclerosis" is an intimal lipid-rich plaque disease of larger arteries. "Arteriolosclerosis" concerns arterioles. "Lipohyalinosis" and "fibrinoid necrosis" describe particular histologic patterns, not universal synonyms for every non-amyloid cSVD lesion. In brain aging literature, brain arteriolosclerosis (B-ASC) is often the preferred pathology label, but definitions and sampling protocols still vary.

2. Anatomy: the route from surface artery to tissue

Pial arteries travel along the brain surface. Penetrating arterioles enter the cortex and deep structures, branch into precapillary arterioles and capillaries, and drain through venules. Unlike many systemic vascular beds, the brain operates inside a rigid skull, requires continuous high-energy supply, and has tight barrier and flow regulation.

The neurovascular unit includes endothelial cells, basement membrane, pericytes, vascular smooth-muscle cells, astrocytic endfeet, neurons, microglia, extracellular matrix, and perivascular immune cells. The cerebral arteriolar vascular unit emphasizes the same coordinated system around arterioles. Injury to one component can alter flow, barrier integrity, immune signaling, or waste clearance in the others.

Four functions to keep separate

Delivery: oxygen and substrate reach tissue through blood flow.
Autoregulation and reactivity: vascular tone adjusts to blood pressure, carbon dioxide, neural activity, and metabolic demand.
Barrier function: endothelial junctions and associated cells restrict uncontrolled movement between blood and brain.
Fluid and solute clearance: interstitial and cerebrospinal fluids exchange and drain along perivascular routes. Competing or complementary models include intramural periarterial drainage (IPAD), glymphatic flow, diffusion, dispersion, and lymphatic outflow.

The direction, driving forces, and relative contributions of these clearance routes in humans remain debated. Enlarged MRI-visible perivascular spaces do not directly measure flow.

3. Brain arteriolosclerosis

Pathology

B-ASC is commonly recognized as hyaline, relatively acellular wall thickening with loss or degeneration of smooth-muscle elements and narrowing or distortion of the lumen in small vessels. Semiquantitative neuropathology scales commonly range from none to severe. Quantitative approaches include a sclerotic index, often written as 1 - (internal diameter / external diameter), but section angle, tissue processing, vessel selection, region, and collapsing of the lumen can bias measurement.

The 2021 Blevins review is essential because it makes three points that are easy to miss:

B-ASC is extremely common in the oldest-old yet understudied.
There is no single universally applied diagnostic and sampling method.
The label may contain biologically different subtypes rather than one homogeneous disease.

Candidate causal pathways

chronic pressure and pulsatility stress transmitted to penetrating vessels;
endothelial dysfunction and blood-brain barrier leakage;
smooth-muscle and pericyte injury;
extracellular-matrix remodeling and fibrosis;
impaired autoregulation and cerebrovascular reactivity;
hypoperfusion or unstable perfusion;
inflammation, oxidative stress, metabolic dysfunction, and cellular senescence;
impaired perivascular fluid handling;
reciprocal interactions with autonomic regulation and systemic vascular disease.

These pathways can coexist. Hypertension may cause arteriolar remodeling, but arteriolar dysfunction could also impair central regulation of systemic physiology. Cross-sectional autopsy associations cannot establish that direction.

Expected injury pattern, with important exceptions

Because non-amyloid arteriopathy often involves deep penetrating vessels, it is associated with deep intracerebral hemorrhage, deep microbleeds, lacunes, white-matter injury, and small subcortical infarcts. However, the mapping is not exclusive. The Perosa et al. 2023 pathology study showed that arteriolosclerosis can underlie lobar microbleeds in cases falsely classified as CAA, especially when lesions were juxtacortical or in subcortical white matter rather than centered in the cortical ribbon.

That result does not invalidate Boston criteria. It demonstrates why a high-performing probabilistic rule is not equivalent to perfect lesion-level specificity.

4. Cerebral amyloid angiopathy

Pathology and distribution

CAA is defined by amyloid deposition in small vessels of the leptomeninges and cerebral cortex, with variable capillary involvement. Deep penetrating arterioles of basal ganglia, thalamus, and brainstem are generally spared in typical sporadic CAA. The vessel wall can progress from focal deposits around smooth-muscle cells to circumferential replacement, loss of wall elements, cracking or double-barrel change, fibrinoid remodeling, and rupture.

Two common neuropathologic patterns are often discussed:

CAA type 1: cortical capillary involvement is present; more strongly associated with APOE ε4 and Alzheimer disease-related biology.
CAA type 2: amyloid is present in leptomeningeal and cortical arteries/arterioles without capillary involvement.

Severity, distribution, and vasculopathic change matter. A binary CAA-present/absent label discards biologically important information.

Relationship to Alzheimer disease

CAA and Alzheimer disease frequently coexist because both involve Aβ, age, and APOE-related susceptibility. They are not interchangeable:

vascular deposits are relatively enriched for Aβ40, while plaques are relatively enriched for Aβ42;
CAA has a characteristic leptomeningeal/cortical vascular distribution;
CAA can occur without advanced Alzheimer disease, especially in hereditary forms;
Alzheimer disease can occur with little or no CAA;
cognitive effects can be additive or interactive through infarction, disconnection, impaired vascular reactivity, inflammation, and hemorrhage.

Analyses that call all amyloid-related signal "Alzheimer pathology" erase this distinction.

The four-stage progression framework

Koemans and colleagues proposed a useful, explicitly provisional sequence:

Initial vascular amyloid deposition. Soluble Aβ handling and vascular deposition change before overt tissue injury.
Altered vascular physiology. Reactivity, pulsatility, barrier function, and clearance become abnormal.
Non-hemorrhagic brain injury. White-matter microstructural damage, cortical microinfarcts, network disconnection, and cognitive effects emerge.
Hemorrhagic lesions. Lobar microbleeds, convexity subarachnoid hemorrhage, cortical superficial siderosis, and lobar intracerebral hemorrhage appear.

Hereditary Dutch-type CAA data suggest that this evolution may span decades. The framework is valuable because it predicts a long prehemorrhagic intervention window. It remains a model, not a proven invariant sequence for every sporadic case.

How a CAA vessel may rupture

The intuitive model is simple mechanical weakening by accumulating amyloid. Human ex vivo MRI-pathology work adds a more dynamic possibility: the final rupture site can contain little detectable amyloid and show fibrinoid remodeling, leakage, smooth-muscle loss, astrocytic and microglial activation, and perivascular inflammation. One interpretation is that amyloid initiates injury, followed by local remodeling or clearance that leaves a structurally fragile segment. This is supported by small, carefully localized pathology studies but is not yet a complete causal account.

5. Perivascular clearance: one of the field's central debates

Soluble Aβ is produced in brain tissue and must be cleared. A major hypothesis is that Aβ moves along basement membranes of capillaries and arteries toward extracranial drainage pathways. Aging, stiffening, loss of smooth-muscle function, altered pulsatility, basement-membrane change, or obstruction by deposited Aβ could impair this clearance and create a feed-forward loop.

Evidence supporting the concept includes:

vascular anatomy and tracer studies in experimental systems;
preferential amyloid deposition along vessels and drainage-relevant compartments;
association between severe centrum semiovale perivascular spaces and CAA;
ex vivo work linking white-matter perivascular-space dilation to vascular Aβ in the overlying cortex;
hereditary CAA observations suggesting physiologic dysfunction before hemorrhage.

Important counterweights are:

rodents and humans differ in anatomy, scale, sleep, posture, heart rate, and experimental conditions;
fixation and postmortem intervals alter spaces and fluid distributions;
MRI-visible PVS are structural spaces, not direct measures of solute direction or speed;
IPAD, glymphatic, diffusion, dispersion, venous, and lymphatic models use overlapping terms but make different mechanistic claims;
amyloid deposition may itself enlarge spaces, reverse causality, or share an upstream cause with PVS dilation.

The best current position is not "CAA is proven to be a clearance disease." It is that impaired perivascular handling is a strong mechanistic candidate requiring human, directional, longitudinal validation.

6. From vessel injury to visible brain injury

Ischemic and non-hemorrhagic consequences

Recent small subcortical infarct: imaging evidence of a recent infarction in one perforating-arteriole territory.
Lacune: a fluid-filled subcortical cavity, generally up to 15 mm, representing the healed end stage of several possible small lesions.
White matter hyperintensity (WMH): T2/FLAIR hyperintensity without CSF-like cavitation. Histology can include myelin loss, axonal damage, gliosis, rarefaction, edema, and small infarcts; etiology is not specific.
Cortical microinfarct: a microscopic ischemic lesion, only a subset of which is visible on conventional MRI. High-resolution MRI detects more but introduces new mimics and thresholds.
Diffusion microstructural injury: altered mean diffusivity, fractional anisotropy, free water, and network metrics may reveal damage before a lesion becomes visible.
Atrophy: downstream volume loss that can be vascular, neurodegenerative, or mixed.

Hemorrhagic consequences

Cerebral microbleed (CMB): a small susceptibility signal void with blooming, generally 2-5 mm but sometimes operationalized up to 10 mm. It represents hemosiderin from prior leakage/bleeding, not necessarily an active bleed.
Cortical superficial siderosis (cSS): chronic blood-breakdown products along the superficial cortex, often interpreted as the residue of repeated convexity subarachnoid bleeding in CAA.
Convexity subarachnoid hemorrhage (cSAH): acute blood in cortical sulci over the convexity; in older patients CAA is important, but venous thrombosis, vasoconstriction, vasculitis, and other causes must be excluded.
Intracerebral hemorrhage (ICH): a macrohemorrhage. Lobar location favors CAA; deep location favors non-amyloid arteriopathy. Cerebellar location is anatomically heterogeneous and is not counted as lobar or deep in Boston v2.0.

Mimics are part of the definition

Susceptibility lesions can be vessels, calcification, cavernomas, trauma-related deposits, or artifacts. PVS can mimic lacunes; lacunes can be confused with old hemorrhage; WMH can reflect demyelination, inflammation, edema, toxic-metabolic injury, or genetic disease. A research protocol must define acquisition, planes, size, signal behavior, anatomic boundaries, and adjudication.

7. The clinical spectrum

cSVD is not synonymous with a stroke seen on a scan. Its manifestations include:

lacunar ischemic stroke and deep or lobar hemorrhage;
cognitive slowing, executive dysfunction, reduced processing speed, and later multidomain impairment;
gait slowing, balance impairment, falls, parkinsonian features, and loss of independence;
apathy, depression, emotional dysregulation, urinary symptoms, and neurobehavioral change;
subtle accumulated disability despite no recognized stroke;
acute or subacute inflammatory syndromes.

CAA has several particularly characteristic presentations:

lobar ICH;
transient focal neurologic episodes (TFNEs or "amyloid spells"), often spreading positive or negative sensory/motor symptoms related to cSAH/cSS and cortical spreading depolarization rather than embolic TIA;
progressive cognitive impairment from non-hemorrhagic injury, network disruption, coexisting Alzheimer disease, and hemorrhagic lesions;
CAA-related inflammation (CAA-ri), with subacute cognitive/behavioral change, headache, seizures, focal deficits, asymmetric vasogenic edema, and hemorrhagic markers;
treatment-associated ARIA in the context of anti-Aβ immunotherapy, which is biologically adjacent to CAA but not identical to spontaneous CAA-ri.

8. Why cognition is hard to attribute

Older brains usually contain several pathologies. A person can have B-ASC, CAA, Alzheimer disease neuropathologic change, LATE-NC, Lewy body disease, atherosclerosis, infarcts, and hippocampal sclerosis together. Their clinical effects can be additive, synergistic, thresholded by brain reserve, or partly redundant.

Important examples from the supplied literature are:

B-ASC remains associated with cognition after adjustment for common neurodegenerative and vascular lesions in several autopsy cohorts.
Multiregional arteriolosclerosis is associated with hippocampal sclerosis of aging, but that association does not prove a direct causal chain.
The medial temporal lobe is a convergence zone for vascular injury, tau, TDP-43, neuronal loss, and distinctive vascular architecture.
Vessel density can correlate with tau and TDP-43 burden, yet a correlation can represent angiogenesis, selective survival, regional anatomy, compensation, or measurement effects.

The right question is rarely "vascular or neurodegenerative?" A better question is "which pathologies, in which regions and time windows, explain unique or interacting variance in which clinical domains?"

9. How to interpret diagnostic criteria

Criteria are engineered for a context of use. Boston v2.0 aims to identify sporadic CAA in patients aged 50 or older with a compatible clinical presentation and appropriate MRI. It is not a population-screening definition of all preclinical CAA. Edinburgh criteria address CAA probability in lobar ICH using acute CT features and, when available, APOE. STRIVE-2 standardizes lesion description for research; it does not diagnose a specific vessel-wall disease.

Four distinctions matter:

Rule-in versus rule-out: probable CAA prioritizes useful specificity; possible CAA captures a broader, less specific group.
Accuracy versus prevalence: positive predictive value changes when criteria are applied to a population with different disease prevalence.
Patient-level versus lesion-level truth: a person can meet probable CAA criteria while one particular lobar microbleed was caused by another pathology.
Clinical validation versus biological completeness: criteria can work well while omitting early physiology or molecular biomarkers.

10. What the field knows with relatively high confidence

cSVD is heterogeneous and is a major contributor to stroke, cognitive impairment, gait dysfunction, and disability.
CAA and arteriolosclerosis are distinct vessel-wall pathologies that frequently coexist.
Routine MRI mostly detects consequences, not the small vessel wall directly.
Lesion distribution carries etiologic information but is not perfectly specific.
CAA can cause hemorrhagic and non-hemorrhagic injury and contributes to cognitive impairment independent of a large symptomatic hemorrhage.
B-ASC is common, clinically consequential, and methodologically under-standardized.
Mixed vascular and neurodegenerative pathology is the rule in advanced age.
MRI acquisition and processing choices substantially change visible lesion counts.
Pathology remains the reference standard for definite CAA and direct assessment of B-ASC, but pathology has its own sampling and temporal limitations.

11. What remains unsettled

the dominant human routes and driving forces for perivascular clearance;
whether BBB leakage is an initiating event, consequence, or both in different cSVD subtypes;
how many biologically distinct processes are hidden inside the label B-ASC;
how to diagnose prehemorrhagic CAA specifically during life;
which WMH, PVS, diffusion, or vascular-reactivity patterns truly distinguish CAA from arteriolosclerosis;
how CAA, B-ASC, Alzheimer pathology, LATE-NC, and hippocampal sclerosis interact regionally and temporally;
which biomarkers are sufficiently robust, diverse, and treatment-responsive for clinical trials;
whether modifying a biomarker changes clinically meaningful outcomes;
how anti-amyloid treatment perturbs vascular amyloid and why severe ARIA occurs in a small subset.

12. A researcher's working mental model

For every observation, write down six fields:

Level: risk factor, vessel wall, physiology, tissue, imaging, or clinical.
Time: before, near, or after the outcome of interest.
Location: cortical ribbon, juxtacortical white matter, deep white matter, deep gray nuclei, brainstem, cerebellum, leptomeninges, or vessel compartment.
Specificity: which competing processes can produce the same observation?
Reference: tissue, longitudinal outcome, another biomarker, expert label, or no independent reference.
Context of use: discovery, diagnosis, prognosis, monitoring, trial enrichment, or mechanism.

This six-field discipline is the shortest route from superficial familiarity to research-grade understanding.

Core references

Blevins BL, et al. Brain arteriolosclerosis. *Acta Neuropathologica*. 2021;141:1-24. doi:10.1007/s00401-020-02235-6
Charidimou A, et al. Emerging concepts in sporadic cerebral amyloid angiopathy. *Brain*. 2017;140:1829-1850. doi:10.1093/brain/awx047
Duering M, et al. Neuroimaging standards for research into small vessel disease - advances since 2013. *Lancet Neurology*. 2023;22:602-618. doi:10.1016/S1474-4422(23)00131-X00131-X)
Greenberg SM. Cerebral Amyloid Angiopathy. *New England Journal of Medicine*. 2026;394:1836-1845. doi:10.1056/NEJMra2411298
Koemans EA, et al. Progression of cerebral amyloid angiopathy: a pathophysiological framework. *Lancet Neurology*. 2023;22:632-642. doi:10.1016/S1474-4422(23)00114-X00114-X)
Perosa V, et al. Histopathological correlates of lobar microbleeds in false-positive cerebral amyloid angiopathy cases. *Annals of Neurology*. 2023;94:856-870. Journal record
van Veluw SJ, et al. Is CAA a perivascular brain clearance disease? *Cellular and Molecular Life Sciences*. 2024;81:239. doi:10.1007/s00018-024-05277-1